Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ADH1A | P07327 | 2/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114282 | 0.80 | TP53 (0.38) | TP53LMNAJAK2ALDH1A1MEN1 | |
| SCHEMBL16114911 | 0.80 | TP53 (0.38) | TP53LMNAJAK2ALDH1A1MEN1 | |
| SCHEMBL16115065 | 0.78 | OPRK1 (0.39) | TP53LMNAJAK2ALDH1A1MEN1 | |
| SCHEMBL16115369 | 0.69 | TP53 (0.39) | TP53LMNAJAK2ALDH1A1MEN1 | |
| SCHEMBL16114963 | 0.69 | OPRK1 (0.44) | TP53LMNAJAK2ALDH1A1MEN1 | |
| SCHEMBL16120477 | 0.68 | TP53 (0.35) | TP53LMNAJAK2ADH1AADH1C | |
| SCHEMBL16115001 | 0.68 | OPRK1 (0.56) | — | |
| SCHEMBL16141806 | 0.68 | KMT2A (0.41) | LMNAKMT2AGAAADORA2A | |
| SCHEMBL16119857 | 0.65 | TP53 (0.43) | TP53LMNAJAK2ALDH1A1MEN1 | |
| SCHEMBL31217358 | 0.64 | GBA1 (0.56) | TP53LMNAJAK2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533977-B2 | Oxazolidinone derivative as CETP inhibitor, its preparation method, and pharmaceutical composition comprising the same | DONG-A ST CO., LTD. (KR) | 2017-01-03 | — | — | US | disclosed |
| US-9533977-B2 | Oxazolidinone derivative as CETP inhibitor, its preparation method, and pharmaceutical composition comprising the same | DONG-A ST CO., LTD. (KR) | 2017-01-03 | — | — | US | disclosed |
| US-20160039804-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A ST CO., LTD. (KR) | 2016-02-11 | — | — | US | disclosed |
| US-20160039804-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A ST CO., LTD. (KR) | 2016-02-11 | — | — | US | disclosed |
| US-20160039804-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A ST CO., LTD. (KR) | 2016-02-11 | — | — | US | disclosed |
| EP-2978761-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dong-A ST Co., Ltd. (KR) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014157994-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A ST CO.,LTD (KR) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014157994-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A ST CO.,LTD (KR) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039804-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CETP, MTTP, APOB | TP53 4511/4885LMNA 829/4885JAK2 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.